shares rose after the company reported positive results from a trial of its insomnia drug Lunesta in menopausal women.
Of 410 women who took part in the trial, those given Lunesta fell asleep significantly faster and slept longer than the study participants who were given a placebo.
The study also showed that the drug improved patients' sleep quality, depth of sleep, daytime alertness, ability to function and concentrate, as well as their physical well being.
Additionally, the study included premenopausal women who were also experiencing insomnia, which is often caused by waking during the night because of hot flashes.
Sepracor's shares were up 4.8% to $57.92.